{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Comprehensive+Oral+Evaluation&page=2", "query": { "intervention": "Comprehensive Oral Evaluation", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Comprehensive+Oral+Evaluation&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T09:36:12.307Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04300998", "title": "Study of CAR-T Therapy in Older Patients", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma", "Refractory B-Cell Lymphoma", "Lymphoma, B-Cell", "DLBCL NOS", "High-grade B-cell Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "Activities of Daily Living/ADLs", "type": "BEHAVIORAL" }, { "name": "Instrumental Activity of Daily Living", "type": "BEHAVIORAL" }, { "name": "Timed Up and Go", "type": "BEHAVIORAL" }, { "name": "Cognition", "type": "BEHAVIORAL" }, { "name": "Geriatric Depression Scale", "type": "BEHAVIORAL" }, { "name": "Social Support", "type": "BEHAVIORAL" }, { "name": "Brief Test of Attention", "type": "BEHAVIORAL" }, { "name": "Trail Making Test", "type": "BEHAVIORAL" }, { "name": "Controlled Oral Word Association Test", "type": "BEHAVIORAL" }, { "name": "Hopkins Verbal Learning Test-Revised", "type": "BEHAVIORAL" }, { "name": "Blood draw", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 154, "start_date": "2020-03-04", "completion_date": "2027-03-04", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-09-25T09:36:12.307Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04300998" }, { "nct_id": "NCT06503978", "title": "Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autism Spectrum Disorder", "Gastro-Intestinal Disorder", "Constipation", "Diarrhea" ], "interventions": [ { "name": "MTP-101P", "type": "COMBINATION_PRODUCT" }, { "name": "Vancomycin", "type": "COMBINATION_PRODUCT" }, { "name": "Miralax", "type": "COMBINATION_PRODUCT" }, { "name": "Antacid", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo MTP-101P", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo Vancomycin", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Gut-Brain-Axis Therapeutics Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "4 Years to 18 Years" }, "enrollment_count": 60, "start_date": "2024-08-20", "completion_date": "2026-08-17", "has_results": false, "last_update_posted_date": "2024-09-25", "last_synced_at": "2026-09-25T09:36:12.307Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06503978" }, { "nct_id": "NCT01361113", "title": "Neoadjuvant Pazopanib in Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2011-06", "completion_date": "2017-02-15", "has_results": true, "last_update_posted_date": "2018-04-25", "last_synced_at": "2026-09-25T09:36:12.307Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Houston, Texas", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01361113" }, { "nct_id": "NCT07322406", "title": "Kaempferol Absorption and Pharmacokinetics Evaluation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "No Disease", "Mitochondria Health", "Longevity", "Pharmacokinetics and Biological Absorption of Kaempferol in Healthy Adult", "Healthy Volunteers" ], "interventions": [ { "name": "Kaempferol", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 120, "start_date": "2025-12-09", "completion_date": "2027-12-22", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-09-25T09:36:12.307Z", "location_count": 3, "location_summary": "New York, New York • Chapel Hill, North Carolina • Pittsburgh, Pennsylvania", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07322406" }, { "nct_id": "NCT05826964", "title": "Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "ER-positive Breast Cancer", "HER2-negative Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "AI+CDK4/6i", "type": "DRUG" }, { "name": "SERD+CDK4/6i", "type": "DRUG" }, { "name": "mTOR inhibitor + AI", "type": "DRUG" }, { "name": "mTOR inhibitor + SERD", "type": "DRUG" }, { "name": "mTOR inhibitor + Selective estrogen receptor modulator", "type": "DRUG" }, { "name": "PI3K inhibitor + SERD", "type": "DRUG" }, { "name": "PI3K inhibitor + AI", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Oral SERD", "type": "DRUG" }, { "name": "PARPi", "type": "DRUG" }, { "name": "AKT inhibitor", "type": "DRUG" }, { "name": "Step 3 Arm 2", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2023-06-12", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-09-25T09:36:12.307Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05826964" }, { "nct_id": "NCT05307939", "title": "A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HPV", "Oropharynx Cancer", "HPV-Related Carcinoma", "HPV-Related Malignancy", "HPV Positive Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "HPV ctDNA Assay", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI Studies", "type": "DIAGNOSTIC_TEST" }, { "name": "EORTC QLQ H&N 35 and C30", "type": "BEHAVIORAL" }, { "name": "MDADI-HN", "type": "BEHAVIORAL" }, { "name": "COST-FACIT", "type": "BEHAVIORAL" }, { "name": "Intensity-Modulated Radiation Therapy (Arm A)", "type": "RADIATION" }, { "name": "Chemoradiation (Arm B)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "BEHAVIORAL", "RADIATION", "COMBINATION_PRODUCT" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-03-24", "completion_date": "2027-03-24", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-25T09:36:12.307Z", "location_count": 8, "location_summary": "Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05307939" }, { "nct_id": "NCT04616963", "title": "Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hiv", "Hormone Therapy" ], "interventions": [ { "name": "Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg", "type": "DRUG" }, { "name": "Emtricitabine Tenofovir Alafenamide 200/25 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2019-10-24", "completion_date": "2024-01-31", "has_results": false, "last_update_posted_date": "2023-05-06", "last_synced_at": "2026-09-25T09:36:12.307Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04616963" }, { "nct_id": "NCT04704297", "title": "Trigger Point Injection for Myofascial Pain Syndrome in the Low Back: A Randomized Controlled Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Low Back Pain", "Myofascial Pain Syndrome Lower Back" ], "interventions": [ { "name": "Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.", "type": "DRUG" }, { "name": "Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.", "type": "DRUG" }, { "name": "Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Madigan Army Medical Center", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2020-12-28", "completion_date": "2022-07-01", "has_results": false, "last_update_posted_date": "2021-01-12", "last_synced_at": "2026-09-25T09:36:12.307Z", "location_count": 1, "location_summary": "Tacoma, Washington", "locations": [ { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04704297" }, { "nct_id": "NCT07227454", "title": "A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Depressive Disorder, Major" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Oral Placebo", "type": "OTHER" }, { "name": "Intranasal Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 258, "start_date": "2026-01-08", "completion_date": "2031-09-15", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-25T09:36:12.307Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227454" }, { "nct_id": "NCT07686731", "title": "Suvorexant 3 - PE-PC", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "PTSD - Post Traumatic Stress Disorder", "Insomnia", "TBI (Traumatic Brain Injury)" ], "interventions": [ { "name": "Suvorexant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Prolonged Exposure Therapy for Primary Care (PE-PC)", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Northern California Institute of Research and Education", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 142, "start_date": "2026-09-01", "completion_date": "2029-08-30", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-09-25T09:36:12.307Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07686731" } ] }